Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 469 to 472 of 472 entries
Sorted by: Best Match Show Resources per page
Clinicopathologic characteristics of laryngeal chondrosarcoma: An analysis of the National Cancer Database.

Auris, nasus, larynx

Adeola JO, Patel JS, Povolotskiy R, Barinsky GL, Grube JG, Hsueh WD, Baredes S, Eloy JA.
PMID: 33812757
Auris Nasus Larynx. 2021 Oct;48(5):956-962. doi: 10.1016/j.anl.2021.02.014. Epub 2021 Mar 31.

OBJECTIVES: Laryngeal Chondrosarcoma (LC) is a rare malignancy with limited studies documenting its clinicopathologic characteristics and treatment options. This study reports demographic and clinical determinants of outcomes for this rare tumor.METHODS: The National Cancer Database (NCDB) was queried for...

Cite
Adeola JO, Patel JS, Povolotskiy R, et al. Clinicopathologic characteristics of laryngeal chondrosarcoma: An analysis of the National Cancer Database. Auris Nasus Larynx. 2021;48(5):956-962doi: 10.1016/j.anl.2021.02.014.
Adeola, J. O., Patel, J. S., Povolotskiy, R., Barinsky, G. L., Grube, J. G., Hsueh, W. D., Baredes, S., & Eloy, J. A. (2021). Clinicopathologic characteristics of laryngeal chondrosarcoma: An analysis of the National Cancer Database. Auris, nasus, larynx, 48(5), 956-962. https://doi.org/10.1016/j.anl.2021.02.014
Adeola, Janet O, et al. "Clinicopathologic characteristics of laryngeal chondrosarcoma: An analysis of the National Cancer Database." Auris, nasus, larynx vol. 48,5 (2021): 956-962. doi: https://doi.org/10.1016/j.anl.2021.02.014
Adeola JO, Patel JS, Povolotskiy R, Barinsky GL, Grube JG, Hsueh WD, Baredes S, Eloy JA. Clinicopathologic characteristics of laryngeal chondrosarcoma: An analysis of the National Cancer Database. Auris Nasus Larynx. 2021 Oct;48(5):956-962. doi: 10.1016/j.anl.2021.02.014. Epub 2021 Mar 31. PMID: 33812757.
Copy Download .nbib Format: NLM
Nanocrystal-based 3D-printed tablets: Semi-solid extrusion using melting solidification printing process (MESO-PP) for oral administration of poorly soluble drugs.

International journal of pharmaceutics

Lopez-Vidal L, Real JP, Real DA, Camacho N, Kogan MJ, Paredes AJ, Palma SD.
PMID: 34813905
Int J Pharm. 2022 Jan 05;611:121311. doi: 10.1016/j.ijpharm.2021.121311. Epub 2021 Nov 20.

This is the first report on the inclusion of nanocrystals (NCs) within 3D-printed oral solid dosage forms -3D-printed tablets or printlets- produced by the Melting Solidification Printing Process (MESO-PP) 3D printing technique. This method allowed the incorporation of albendazole...

Cite
Lopez-Vidal L, Real JP, Real DA, et al. Nanocrystal-based 3D-printed tablets: Semi-solid extrusion using melting solidification printing process (MESO-PP) for oral administration of poorly soluble drugs. Int J Pharm. 2021;611:121311doi: 10.1016/j.ijpharm.2021.121311.
Lopez-Vidal, L., Real, J. P., Real, D. A., Camacho, N., Kogan, M. J., Paredes, A. J., & Palma, S. D. (2022). Nanocrystal-based 3D-printed tablets: Semi-solid extrusion using melting solidification printing process (MESO-PP) for oral administration of poorly soluble drugs. International journal of pharmaceutics, 611121311. https://doi.org/10.1016/j.ijpharm.2021.121311
Lopez-Vidal, Lucía, et al. "Nanocrystal-based 3D-printed tablets: Semi-solid extrusion using melting solidification printing process (MESO-PP) for oral administration of poorly soluble drugs." International journal of pharmaceutics vol. 611 (2022): 121311. doi: https://doi.org/10.1016/j.ijpharm.2021.121311
Lopez-Vidal L, Real JP, Real DA, Camacho N, Kogan MJ, Paredes AJ, Palma SD. Nanocrystal-based 3D-printed tablets: Semi-solid extrusion using melting solidification printing process (MESO-PP) for oral administration of poorly soluble drugs. Int J Pharm. 2022 Jan 05;611:121311. doi: 10.1016/j.ijpharm.2021.121311. Epub 2021 Nov 20. PMID: 34813905.
Copy Download .nbib Format: NLM
Improving the in vitro dissolution rate and pharmacokinetic performance of fenbendazole in sheep using drug nanocrystals.

Research in veterinary science

Melian ME, Ibarra M, Ceballos L, Paredes AJ, Munguía B, Faccio R, Palma S, Álvarez LI, Domínguez L.
PMID: 34922278
Res Vet Sci. 2021 Dec 07;142:110-116. doi: 10.1016/j.rvsc.2021.12.001. Epub 2021 Dec 07.

Benzimidazole methylcarbamate anthelmintics, including fenbendazole (FBZ), have only limited water solubility and small differences in drug solubility may have a major influence on their absorption, pharmacokinetic behavior and anthelmintic efficacy. To improve FBZ water solubility and dissolution rate, novel...

Cite
Melian ME, Ibarra M, Ceballos L, et al. Improving the in vitro dissolution rate and pharmacokinetic performance of fenbendazole in sheep using drug nanocrystals. Res Vet Sci. 2021;142:110-116doi: 10.1016/j.rvsc.2021.12.001.
Melian, M. E., Ibarra, M., Ceballos, L., Paredes, A. J., Munguía, B., Faccio, R., Palma, S., Álvarez, L. I., & Domínguez, L. (2021). Improving the in vitro dissolution rate and pharmacokinetic performance of fenbendazole in sheep using drug nanocrystals. Research in veterinary science, 142110-116. https://doi.org/10.1016/j.rvsc.2021.12.001
Melian, María Elisa, et al. "Improving the in vitro dissolution rate and pharmacokinetic performance of fenbendazole in sheep using drug nanocrystals." Research in veterinary science vol. 142 (2021): 110-116. doi: https://doi.org/10.1016/j.rvsc.2021.12.001
Melian ME, Ibarra M, Ceballos L, Paredes AJ, Munguía B, Faccio R, Palma S, Álvarez LI, Domínguez L. Improving the in vitro dissolution rate and pharmacokinetic performance of fenbendazole in sheep using drug nanocrystals. Res Vet Sci. 2021 Dec 07;142:110-116. doi: 10.1016/j.rvsc.2021.12.001. Epub 2021 Dec 07. PMID: 34922278.
Copy Download .nbib Format: NLM
Antibiotic Duration After Urethroplasty: An Attempt at Improving Antibiotic Stewardship.

Urology

Baas W, Parker A, Radadia K, Ogawa S, Vetter J, Paradis A, Meyer M, Murphy G.
PMID: 34380052
Urology. 2021 Aug 08; doi: 10.1016/j.urology.2021.07.028. Epub 2021 Aug 08.

OBJECTIVE: To evaluate if decreasing postop abx prophylaxis affects UTI and wound infection rates in patients following urethroplasty.METHODS: A retrospective review of patients who underwent urethroplasty from 9/2017 - 3/2020 by a single surgeon was performed. All patients received...

Cite
Baas W, Parker A, Radadia K, et al. Antibiotic Duration After Urethroplasty: An Attempt at Improving Antibiotic Stewardship. Urology. 2021;doi: 10.1016/j.urology.2021.07.028.
Baas, W., Parker, A., Radadia, K., Ogawa, S., Vetter, J., Paradis, A., Meyer, M., & Murphy, G. (2021). Antibiotic Duration After Urethroplasty: An Attempt at Improving Antibiotic Stewardship. Urology, . https://doi.org/10.1016/j.urology.2021.07.028
Baas, Wesley, et al. "Antibiotic Duration After Urethroplasty: An Attempt at Improving Antibiotic Stewardship." Urology vol. (2021). doi: https://doi.org/10.1016/j.urology.2021.07.028
Baas W, Parker A, Radadia K, Ogawa S, Vetter J, Paradis A, Meyer M, Murphy G. Antibiotic Duration After Urethroplasty: An Attempt at Improving Antibiotic Stewardship. Urology. 2021 Aug 08; doi: 10.1016/j.urology.2021.07.028. Epub 2021 Aug 08. PMID: 34380052.
Copy Download .nbib Format: NLM
Showing 469 to 472 of 472 entries